DOC2B Biomarker Detection for Early β-Cell Dysfunction in Diabetes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic markers for type 1 diabetes (T1D) and type 2 diabetes (T2D) are limited in their ability to accurately predict β-cell destruction and progression to clinical disease, particularly in early stages, and there is a need for better biomarkers to enable early detection, prevention, and treatment.

Innovation Solution

The use of DOC2B expression levels in biological samples, detected through high-throughput screening ELISA, as a biomarker for early-stage T1D and T2D, where reduced DOC2B expression indicates elevated risk or presence of the diseases, allowing for early diagnosis and potential treatment with β-cell transplantation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If autoantibodies are used to predict T1D risk, then screening availability is improved, but measurement precision is limited due to high heterogeneity in T1D progression and inability to track levels after seroconversion

Engineering Contradiction:

Improvescreening availabilityVSAvoidprediction accuracy

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The patent shifts from measuring autoantibody presence/absence to quantifying DOC2B protein expression levels, a continuous parameter that can track disease progression dynamically. This parameter change enables precise monitoring of β-cell function over time rather than static risk assessment.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the autoantibody-based immunological detection system with a protein expression quantification system using ELISA or mass spectrometry. This substitution moves from detecting immune response markers to directly measuring β-cell functional protein levels, providing more direct and accurate disease prediction.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Loss of time

If early biomarkers are used to predict β-cell destruction, then early detection capability is improved, but reliability is limited due to limited availability of accurate biomarkers

Engineering Contradiction:

Improveearly detection timingVSAvoidbiomarker accuracy

Core Design Contradiction:

Loss of timeVSReliability

Solution Approach 1:

The patent uses DOC2B protein as an intermediary marker that reflects β-cell functional status. Rather than directly measuring β-cell destruction, DOC2B serves as a surrogate indicator that correlates with β-cell mass and function, enabling indirect but reliable early detection of disease processes.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent establishes a feedback mechanism where DOC2B levels are monitored over time to track β-cell function dynamics. This longitudinal monitoring provides feedback on disease progression and treatment response, improving both early detection reliability and ongoing disease management.

Inventive Principle:

Principle #23Feedback

3Measurement precision

If DOC2B expression levels are used as a biomarker, then measurement precision is improved for detecting β-cell dysfunction, but device complexity increases due to requirement for specialized detection methods

Engineering Contradiction:

Improveβ-cell dysfunction detection accuracyVSAvoiddetection system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent leverages the universality of ELISA technology, which is a well-established, multi-functional platform used for detecting various proteins. By adapting this existing technology for DOC2B detection, the patent avoids developing entirely new complex detection systems while achieving precise measurement of β-cell function.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs established detection methodologies (ELISA, mass spectrometry) that have been successfully applied to other protein markers. These proven techniques serve as templates or copies that can be adapted for DOC2B detection, reducing the need to invent entirely new complex detection systems from scratch.

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

DOC2B serves as a reliable biomarker for early β-cell dysfunction, enabling non-invasive diagnosis and potential prevention of T1D and T2D by detecting reduced expression levels, and its restoration post-islet transplantation indicates functional β-cell mass, supporting targeted interventions.

Implementation Method 1

detecting the level of DOC2B expression comprises detecting the level of DOC2B protein or the level of DOC2B mRNA in the biological sample

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS20260023074A1DOC2b as a biomarker for type 1 and type 2 diabetes

Publication Date: 2026.01.22 CITY OF HOPE

AI summary

Disclosed is the use of DOC2B as an early stage biomarker for diagnosing type 1 diabetes (T1D), pre-T1D, type 2 diabetes (T2D), pre-T2D or for assessing the risk of T1D, pre-T1D, T2D, or pre-T2D. Also disclosed are methods of in vivo diagnosing T1D, pre-T1D, T2D, or pre-T2D or assessing the risk of T1D, pre-T1D, T2D, or pre-T2D by detecting a reduced level of DOC2B expression in a biological sample including blood, plasm, serum, platelets, and pancreatic islets.